Apimeds Pharmaceuticals US (APUS) Balance Sheet: Assets & Liabilities

Apimeds Pharmaceuticals US (APUS) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Apimeds Pharmaceuticals US reported total assets of $164.18M and total liabilities of $10.84M. Shareholders' equity was $153.35M. Total debt stood at $7.72M against $3.64M in cash and short-term investments, a net debt position of $4.08M. That puts debt-to-equity at 0.05.

Apimeds Pharmaceuticals US Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Apimeds Pharmaceuticals US, Inc. (APUS) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Current Assets
Cash and Cash Equivalents	1.64	0.00	0.41	0.01	0.17
Short-Term Investments	2.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	3.64	0.00	0.41	0.01	0.17
Accounts Receivable	0.00	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00
Other Current Assets	0.05	0.01	0.01	0.00	0.00
Total Current Assets	13.98	0.01	0.42	0.01	0.17
Non-Current Assets
Property, Plant & Equipment (Net)	0.24	0.00	0.00	0.00	0.00
Long-Term Investments	149.89	0.00	0.00	0.00	0.00
Other Non-Current Assets	0.08	0.00	0.00	0.00	0.00
Total Non-Current Assets	150.20	0.00	0.00	0.00	0.00
Total Assets	164.18	0.01	0.42	0.01	0.17
Current Liabilities
Accounts Payable	0.92	0.59	0.00	0.04	0.01
Short-Term Debt	7.59	0.33	0.00	0.26	0.00
Current Portion of Long-Term Debt	7.09	-	-	-	-
Accrued Liabilities	0.53	0.11	0.07	0.04	-
Other Current Liabilities	1.62	0.77	0.12	0.02	0.00
Total Current Liabilities	10.71	1.02	0.12	0.32	0.01
Non-Current Liabilities
Long-Term Debt	0.13	0.35	0.27	0.40	0.40
Other Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00
Total Non-Current Liabilities	0.13	0.35	0.27	0.40	0.40
Total Liabilities	10.84	1.37	0.39	0.72	0.41
Stockholders' Equity
Common Stock	0.13	0.08	0.21	0.10	0.10
Retained Earnings	-10.39	-4.39	-3.00	-2.22	-1.56
Additional Paid-in Capital	163.54	2.95	2.83	1.41	1.22
Shares Outstanding	1.26	1.16	1.16	1.16	11.57
Total Stockholders' Equity	153.35	-1.36	0.03	-0.71	-0.24
Total Liabilities & Equity	164.18	0.01	0.42	0.01	0.17

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Apimeds Pharmaceuticals US Balance Sheet

How much debt does Apimeds Pharmaceuticals US have?

Apimeds Pharmaceuticals US had total debt of $7.72M as of Dec 31, 2025, against $3.64M in cash and short-term investments. Its debt-to-equity ratio was 0.05. Total debt was $673.34K a year earlier.

What are Apimeds Pharmaceuticals US's total assets?

Apimeds Pharmaceuticals US reported total assets of $164.18M as of Dec 31, 2025, up 1257338.4% from $13.06K a year earlier. Total liabilities were $10.84M.

What is Apimeds Pharmaceuticals US's shareholders' equity?

Apimeds Pharmaceuticals US's shareholders' equity was $153.35M as of Dec 31, 2025, or about $121.94 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition